

Isolation and Identification *Enterobacter asburiae* from Consumed Powdered Infant Formula Milk (PIF) in the Neonatal Intensive Care Unit (NICU)

Jalal Mardaneh¹ and Mohammad Mehdi Soltan Dallal^{2,3}

¹ Department of Microbiology, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran

² Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran

³ Division of Bacteriology, Department of Pathobiology and Microbiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Received: 18 Dec. 2013; Accepted: 6 Jun. 2014

Abstract- *Enterobacter asburiae* (*E. asburiae*) is a facultative anaerobic, non-spore-forming gram-negative rod-shaped bacterium belonging to the family of *Enterobacteriaceae*. It is an opportunistic pathogen that its strains are isolated from a variety of clinical and environmental specimens. Since powdered infant formula milk (PIF) is not a sterile product, it is an excellent medium for bacterial growth. The aim of this study was to isolate and identify *E. asburiae* from PIF in the neonatal intensive care unit (NICU) and determine antimicrobial susceptibility patterns of this bacterium. A total 125 PIF samples were purchased from drug stores between June 2011 to March 2012. *E. asburiae* was isolated according to FDA method. For final confirmation, biochemical tests embedded in the API-20E system were used. The drug susceptibility test was performed using the disc diffusion method according to CLSI recommendations. Out of the 125 PIF samples investigated, 2 (1.6%) samples were positive for *E. asburiae*. All isolated strains were uniformly susceptible to aztreonam, cefotaxim, amikacin, streptomycin, nalidixic acid, meropenem, tetracycline, ceftazidime, and colistin. Variable susceptibility was seen to the some antimicrobial agents tested. Each country should categorize its own designed guidelines for the preparation and handling of PIF adapted to the local environment. Moreover, the pathogenesis of the *E. asburiae* in infants hospitalized in NICU and other groups such as immunosuppressed patients and HIV infected individuals is uncertain and requires further study.

© 2015 Tehran University of Medical Sciences. All rights reserved.

Acta Med Iran 2016;54(1):39-43.

Keywords: Powdered infant formula milk (PIF); Neonatal intensive care unit (NICU); *E. asburiae*

Introduction

Enterobacter asburiae (*E. asburiae*) is a motile (by peritrichous flagella), facultative anaerobic, non-spore-forming gram-negative rod-shaped bacterium belonging to the family of *Enterobacteriaceae* (1-3). It is a new species in *Enterobacter* genus that was formerly called as Enteric Group 17. This organism was described and named by Brenner and coworkers in 1986 (4). *E. asburiae* is named in honor of "Mary Alyce Fife-Asbury" an American bacteriologist who made many important contributions to the taxonomy of the *Enterobacteriaceae* family (5). The DNA G + C content of *E. asburiae* is 55 ± 1.1 mol% (4).

E. asburiae have been isolated from soil and water and a variety of human sources including urine, respiratory tracts, stools, wounds, blood, endometrium,

gall bladder, lochia exudate, penis, peritoneal fluid, and synovial fluid (4,6,7). This organism has been isolated from a wide variety of crops such as cotton, cucumber, common bean, and rice (2,8-10).

Some of the *E. asburiae* isolates are identified as human pathogens. *E. asburiae* is an opportunistic pathogen and causes different human diseases such as community-acquired pneumonia, soft tissue infections, wound infection and other infections (3,4,11,12). *E. asburiae* produces the Bush group 1 β -lactamase enzyme constitutively at high levels which causes this bacterium be resistant to most β -lactam antibiotics (13).

This microorganism can cause opportunistic infections in immunocompromised (usually hospitalized) hosts. Before a baby formula was routinely screened for *Enterobacter*, many infants contracted bacterial infections due to this *Enterobacter's* ability to

Corresponding Author: M.M. Soltan Dallal

Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Tel: +98 21 88992971, Fax: +98 21 66462267, E-mail address: msoltandallal@gmail.com

Isolation and identification *enterobacter*

survive the heating preparations of the powdered formula.

Decreased transplacental transfer of maternal immunoglobulin G antibodies and reduced endogenous synthesis of IgG antibody predispose infants born prematurely to nosocomial infections. Neonates, particularly those who are preterm and low birth weight, are at higher risk of acquiring infections compared with the term and older infants. Patients in the neonatal intensive care unit (NICU) are one neonate group most at risk of acquiring healthcare-associated infections (15). Nosocomial infections cause significant morbidity and mortality in NICU hospitalized patients. Cross-transmission of micro-organisms, either directly from the hands or indirectly from environmental sources is a major contributing factor in the current infection threats to hospital inpatients (16).

Enterobacter spp. are the less common cause of hospital-acquired infections in NICUs. The members of this genus are multidrug resistant pathogens and can cause different diseases with high mortality rates in preterm infants. Several outbreaks caused by these opportunistic pathogens have been linked to intrinsically contaminate powdered infant formula (PIF) (17). Underlying diseases, low-birth-weight, immunocompromised immune system, cancer chemotherapy, and intravenous catheterization can be predisposing factors in cases of infections due to unusual microorganisms, including *E. asburiae* in neonates.

There are little information and evidence about the role of powdered infant milk formula in the transmission of opportunistic microorganisms to neonates and NICU hospitalized patients. Contamination of PIF with *E. asburiae* will be associated with the development of disease among neonates. Therefore, the microbiological safety of PIF is of most importance. Because PIF is not a sterile product, it is an excellent medium to support bacterial growth. Bovine milk and plant materials are essential ingredients of PIF and a potential source of various bacteria that are pathogenic to neonates and adults. The aim of this study was to isolate and identify *E. asburiae* from PIF in NICU in Tehran (Iran) hospitals and determine antimicrobial susceptibility patterns of this bacterium.

Materials and Methods

Sampling

A cross-sectional study was carried out on 125 PIF samples purchased from hospital drug stores between Jun 2011 to March 2012.

Isolation and Identification

In this study for isolation *Enterobacter asburiae* from PIF samples, the PIF cans were surface sterilized with 70% ethanol (Merck Co.) and were opened in a laminar flow cabinet. Samples were taken from each product under aseptically conditions. *E. asburiae* was isolated according to FDA method (18,19). We prepared 3 Erlenmeyer flask each of sterile distilled water (pre-warmed to 45°C) at 9, 90 and 900 ml containing 1, 10 and 100 g of PIF, respectively. After the PIF was completely mixed and dissolved in distilled water, it was incubated at 37 °C for 18-24 h. Following incubation, 10 ml of each sample was added to 90 ml of *Enterobacteriaceae* enrichment (EE) broth medium and placed at 37 °C for 18-24 h. After incubation, a lapful of the enrichment culture was streaked onto duplicates violet red bile glucose agar (VRBGA) plates and cultured at 37 °C for 18-24 h. A total of four suspicious colonies were picked from each VRBGA plate, and pure culture was performed. For detection non-lactose fermenting isolates, presumptive colonies were streaked onto MacConkey agar and incubated at 37°C for 72 h. In order that final confirmation; biochemical tests embedded in the API-20E biochemical kit system (Bio-Mérieux) and manual biochemical tests were used according to the directions of the manufacturer. For long term storage, the purified isolates were saved in tryptic soy broth (TSB) with 20% glycerol (Merck Co.) at -20°C.

Antibiotic sensitivity testing

Antibiotic sensitivity testing was done using Kirby-Bauer disk diffusion method on Mueller Hinton agar according to CLSI guidelines (20). Antimicrobial agents used in this study, were tetracycline (30µg), minocycline (30µg), tigecycline (15µg), imipenem (10µg), meropenem (10µg), aztreonam (30µg), ampicillin (10µg), mezlocillin (75µg), ticarcillin (75µg), carbenicillin (100µg), piperacillin (100µg), piperacillin-tazobactam (110µg), cefotaxime (30µg), ceftazidime (30µg), ceftriaxone (30µg), cefepime (30µg), ciprofloxacin (5µg), moxifloxacin (5µg), levofloxacin (5µg), streptomycin (10µg), gentamicin (10µg), amikacin (30µg), tobramycin (10µg), nalidixic acid (30µg), trimethoprim-sulfamethoxazole (25µg), colistin (25µg), and chloramphenicol (30µg).

Results

Out of the 125 PIF samples investigated, 2 (1.6%) of samples were positive for *Enterobacter asburiae*. The

gram staining of the colony of organism showed gram negative rods. On VRBGA agar selective medium purple/pink colored colonies, and on MacConkey agar lactose fermenting, smooth, convex, punctuate, umbilicated, glistening colonies were grown during 16 to 20 hours. Isolated strains were oxidase negative, catalase positive, motile and produced other biochemical reactions which are characteristic of *E. asburiae* (Table 1).

Table 1. Biochemical reactions of *Enterobacter asburiae*

Test	Reaction/Result
Gram stain	Gram-negative, rod
Triple Sugar Iron Agar	Acid (Yellow) slant/ Acid (Yellow) butt. No H ₂ S
Motility	+
Oxidase	-
Catalase	+
Nitrate reduction	+
Simmons Citrate's at 37°C	+
Gas from Glucose	+
Acid from Glucose	+
Lactose	+
Maltose	+
Sucrose	+
Sorbitol	+
Mannitol	+
Xylose	+
Raffinose	+
Arabinose	-
D-Cellobiose	+
Malonate	-
Adonitol	-
Rhamnose	+
Inositol	+
Salicin	+
ONPG	+
Indole	-
Methyl Red (MR)	-
Voges Proskauer (VP)	+
Urease	-
Lysine decarboxylase	-
Ornithine decarboxylase	+
Arginine dehydrolase	+
DNAase	-
Esculin hydrolysis	-
Gelatin hydrolysis	-

All *E. asburiae* strains isolated from PIF samples were uniformly susceptible to aztreonam, cefotaxim, amikacin, streptomycin, nalidixic acid, meropenem, tetracycline, ceftazidime, ciprofloxacin, cefepime, imipenem, levofloxacin, piperacillin-tazobactam, cotrimoxazole, moxifloxacin, and colistin. Variable susceptibility was seen to the other antimicrobial agents tested (Table 2).

Table 2. Antimicrobial susceptibility pattern of *Enterobacter asburiae* strains isolated from PIF. (N=2)

Antibiotic	Sensitive (%)	Intermediate (%)	Resistant (%)
Ampicillin (AP)	1 (50)	-	1 (50)
Amoxicillin (A)	1 (50)	-	1 (50)
Aztreonam (ATM)	2 (100)	-	-
Cefotaxime (CTX)	2 (100)	-	-
Amikacin (AK)	2 (100)	-	-
Streptomycin (S)	2 (100)	-	-
Meropenem (MEM)	2 (100)	-	-
Mezlocillin (MEZ)	1 (50)	1 (50)	-
Nalidixic acid (NA)	2 (100)	-	-
Tigecycline (TGC)	1 (50)	1 (50)	-
Tetracycline (T)	2 (100)	-	-
Ticarcillin (TC)	1 (50)	-	1 (50)
Chloramphenicol (C)	-	1 (50)	1 (50)
Ceftazidime (CAZ)	2 (100)	-	-
Ciprofloxacin (CIP)	2 (100)	-	-
Cefepime (CPM)	2 (100)	-	-
Imipenem (IMI)	2 (100)	-	-
Levofloxacin (LEV)	2 (100)	-	-
Minocycline (MN)	1 (50)	-	1 (50)
Piperacillin (PRL)	1 (50)	-	1 (50)
Piperacillin-tazobactam (PTZ)	2 (100)	-	-
Carbenicillin (PY)	-	1 (50)	1 (50)
Tobramycin (TN)	1 (50)	-	1 (50)
Cotrimoxazole (TS)	2 (100)	-	-
Moxifloxacin (MFX)	2 (100)	-	-
Gentamicin (GM)	1 (50)	1 (50)	-
Colistin (CO)	2 (100)	-	-

Discussion

Many of the bacterial genera included known opportunistic pathogens that have been linked to outbreaks in NICUs. *E. asburiae* is an opportunistic pathogen that its strains are isolated from a variety of clinical and environmental specimens (4,6). Hospitalized infants in NICUs are particularly susceptible to opportunistic infections caused by bacteria, and infected neonates have high morbidity and mortality rates (21).

One of the biggest difficulties in preventing NICU ward and hospital-acquired infections is understanding the sources of the infectious agents and the routes of transmission. The consumption and use of PIF as infant food are wide-spreading; however, few studies have been conducted to evaluate *E. asburiae* role in food safety. Recent food-borne outbreaks traced to infant formula have raised concern about their processing and

handling. PIF, one of the most commonly used infant foods, has been identified as a source of food-borne illness.

To the best of our knowledge, there is no previous report on the isolation and identification *E. asburiae* from powdered infant milk formula milk and determination antimicrobial susceptibility patterns of this bacterium in Iran. Current study indicates that powdered infant milk formula samples are contaminated with *E. asburiae*. It has been isolated from different sources such as clinical specimens, foods, plants, in developed and developing countries (2,4,8-10). The current study showed all *E. asburiae* strains isolated PIF samples are uniformly susceptible to aztreonam, cafotaxim, amikacin, streptomycin, nalidixic acid, meropenem, tetracycline, ceftazidime, ciprofloxacin, cefepime, imipenem, levofloxacin, piperacillin-tazobactam, cotrimoxazole, moxifloxacin, and colistin. In present study, some isolates have variable susceptibility to the other antibiotics tested.

PIF are not sterile products and may contain microorganisms that can cause serious illness in infants, such as *E. asburiae*. Young children, especially infants, are vulnerable to foodborne illness. Babies can have difficulties fighting off infections because their immune systems are not yet fully developed. The infants who are at a higher risk of developing an *E. asburiae* infection include neonates, and those less than two months of age, especially, pre-term, low-birth-weight, HIV positive and immunocompromised infants with weakened immune systems. Infections caused by *E. asburiae* in PIF can be very serious and sometimes fatal.

PIF and other milk products are excellent media for regeneration and replication of potentially pathogenic and opportunistic bacteria. Producers report that, using current methods, it is not possible to omit all microorganisms from PIF in the manufactory (18-20). Inappropriate conditions of production, preparation, and handling of PIF may pose a substantial risk to neonates, preterm infants, and neonatal with weakened immune systems. Each country should categorize its own designed guidelines for the preparation and handling of PIF adapted to the local environment. Staff should be quite trained according to the planed guidelines, and educated in hygiene prescriptions for PIF preparation. Continuous monitoring accomplishment of the guidelines is necessary (22). Infections from resistant bacteria are now too common in worldwide (especially in developing countries), and some pathogens have even become resistant to different classes of antibiotics. Antibiotic-resistant infections can also come from the

food (including PIF) we eat. The bacteria that contaminate food can be resistant because of the use of antibacterial in people and in food animals. HIV positive patients me (AIDS) are also at greater risk of invasive bacterial infections (e.g., foodborne pathogens) than the general population (23-26).

Public health institutes should affirm to parents, health care personnel and carries that PIF is not a sterile product, and good hygiene workouts are required in preparing PIF. Accurate consultation about the safe preparation, handling, and storage of PIF for health care workers in hospitals, especially the staff of intensive care units, and public health centers should be published separately. Moreover, the pathogenesis of the *E. asburiae* in infants hospitalized in an NICU and other groups such as immunosuppressed patients and HIV infected individuals is uncertain and requires further study.

Acknowledgment

This study was supported by Tehran University of medical sciences, Tehran, Iran.

References

1. Hoffmann H, Stindl S, Ludwig W, et al. Reassignment of *Enterobacter dissolvens* to *Enterobacter cloacae* as *E. cloacae* subspecies *dissolvens* comb. nov and emended description of *Enterobacter asburiae* and *Enterobacter kobei*. *Syst Appl Microbiol* 2005;28(3):196-205.
2. Asis CA Jr, Adachi K. Isolation of endophytic diazotroph *Pantoea agglomerans* and nondiazotroph *Enterobacter asburiae* from sweetpotato stem in Japan. *Lett Appl Microbiol* 2004;38(1):19-23.
3. Cha SW, Heo JN, Park CK, et al. *Enterobacter asburiae* Pneumonia with Cavitation. *J Korean Soc Radiol* 2013;68(3):217-9.
4. Brenner DJ, McWhorter A, Kai A, et al. *Enterobacter asburiae* sp. nov., a new species found in clinical specimens, and reassignment of *Erwinia dissolvens* and *Erwinia nimipressuralis* to the genus *Enterobacter* as *Enterobacter dissolvens* comb. nov. and *Enterobacter nimipressuralis* comb. nov. *J Clin Microbiol* 1986;23(6):1114-20.
5. Farmer JJ 3rd, Davis BR, Hickman-Brenner FW, et al. Biochemical identification of new species and biogroups of *Enterobacteriaceae* isolated from clinical specimens. *J Clin Microbiol* 1985;21(1):46-76.
6. Bi C, Rice JD, Preston JF. Complete fermentation of xylose and methylglucuronoxyllose derived from methylglucuronoxylan by *Enterobacter asburiae* strain JDR-1. *Appl Environ Microbiol* 2009;75(2):395-404.

7. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). *J Antimicrob Chemother* 2005;55(6):965-73.
8. Elbeltagy A, Nishioka K, Sato T, et al. Endophytic colonization and in planta nitrogen fixation by a *Herbaspirillum* sp. isolated from wild rice species. *Appl Environ Microbiol* 2001;67(11):5285-93.
9. Siddiqui IA, Shaikat SS. Endophytic colonization of *Phaseolus vulgaris* by *Pseudomonas fluorescens* strain 89B-27 and *Enterobacter asburiae* strain JM22. *Improv Plant Productivity by Rhizosphere Bacteria* 1997;180(1):111-20.
10. McInroy JA, Klopper JW. Survey of indigenous bacterial endophytes from cotton and sweet corn. *Plant Soil* 1995;173(2):337-42.
11. Koth K, Boniface J, Chance EA, et al. *Enterobacter asburiae* and *Aeromonas hydrophila*: soft tissue infection requiring debridement. *Orthopedics* 2012;35(6):e996-9.
12. Stewart JM, Quirk JR. Community-acquired pneumonia caused by *Enterobacter asburiae*. *Am J Med* 2001;111(1):82-3.
13. Pitout JD, Moland ES, Sanders CC, et al. Beta-lactamases and detection of beta-lactam resistance in *Enterobacter* spp. *Antimicrob Agents Chemother* 1997;41(1):35-9.
14. Sheng WH, Badal RE, Hseuh PR. Distribution of Extended-spectrum β -lactamases (ESBLs), AmpC β -lactamases, and Carbapenemases among *Enterobacteriaceae* Isolates Causing Intra-abdominal Infections in Asia-Pacific: the Study for Monitoring Antimicrobial Resistance Trends (SMART). *Antimicrob Agents Chemother* 2013;57(7):2981-8.
15. Callaghan C. Infection control in the neonatal intensive care unit. *Nurs Stand* 2007;22(1):35-41.
16. Pratt RJ, Pellowe CM, Wilson JA, et al. epic2: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. *J Hosp Infect* 2007; 65(Suppl 1):S1-64.
17. Polin RA, Saiman L. Nosocomial Infections in the Neonatal Intensive Care Unit. *Neo Rev* 2003;4(3):81-9.
18. Mardaneh J, Soltan-Dallal MM. Isolation and Identification of *E. cowanii* from Powdered Infant Formula in NICU and Determination of Antimicrobial Susceptibility of Isolates. *Iran J Pediatr* 2014;24(3):261-6.
19. Mardaneh J, Soltan Dallal MM, Taheripoor M, et al. Isolation, Identification and Antimicrobial Susceptibility Pattern of *Tatumella ptyseos* Strains Isolated from Powdered Infant Formula Milk Consumed in Neonatal Intensive Care Unit: First Report from Iran. *Jundishapur J Microbiol* 2014;7(6):e10608.
20. Poorabbas B, Mardaneh J, Rezaei Z, et al. Nosocomial Infections: Multicenter surveillance of antimicrobial resistance profile of *Staphylococcus aureus* and gram negative rods isolated from blood and other sterile body fluids in Iran. *Iran J Microbiol* 2015;7(3):127-35.
21. Hewitt KM, Mannino FL, Gonzalez A, et al. Bacterial Diversity in Two Neonatal Intensive Care Units (NICUs). *PLoS One* 2013;8(1):e54703.
22. Akonor PT, Akonor MA. Food Safety Knowledge: The Case of Domestic Food Handlers in Accra. *Eur J Nutr Food Saf* 2013;3(3):99-111.
23. Mardaneh J, Dallal MM. Isolation, identification and antimicrobial susceptibility of *Pantoea* (*Enterobacter*) agglomerans isolated from consumed powdered infant formula milk (PIF) in NICU ward: First report from Iran. *Iran J Microbiol* 2013;5(3):263-7.
24. Abbasi P, Kargar M, Doosti A, et al. Characterization of Shiga-toxin producing *E. coli* (STEC) and enteropathogenic *E. coli* (EPEC) using multiplex Real-Time PCR assays for *stx1*, *stx2*, *eaeA*. *Iran J Microbiol* 2014;6(3):169-74.
25. Hassanzadeh P, Hassanzadeh Y, Mardaneh J, et al. Isolation of Methicillin-Resistant *Staphylococcus aureus* (MRSA) from HIV Patients Referring to HIV Referral Center, Shiraz, Iran, 2011-2012. *Iran J Med Sci* 2015;40(6):526-30.
26. Anvarinejad M, Pouladfar Gh, Japoni A, et al. Isolation and Antibiotic Susceptibility of the Microorganisms Isolated from Diabetic Foot Infections in Nemazee Hospital, Southern Iran. *J Pathogen* 2015;1-7.